Free Trial

IQVIA (IQV) Competitors

$217.50
+1.25 (+0.58%)
(As of 11:36 AM ET)

IQV vs. ICLR, INCY, MEDP, CRL, NRC, OABI, MXCT, ABSI, LUNA, and NOTV

Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Incyte (INCY), Medpace (MEDP), Charles River Laboratories International (CRL), National Research (NRC), OmniAb (OABI), MaxCyte (MXCT), Absci (ABSI), Luna Innovations (LUNA), and Inotiv (NOTV). These companies are all part of the "commercial physical research" industry.

IQVIA vs.

IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, community ranking, risk, earnings, dividends and valuation.

IQVIA has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$14.98B2.63$1.36B$7.3229.54
ICON Public$8.23B3.19$612.34M$8.2238.78

IQVIA has a net margin of 9.01% compared to ICON Public's net margin of 8.30%. IQVIA's return on equity of 29.17% beat ICON Public's return on equity.

Company Net Margins Return on Equity Return on Assets
IQVIA9.01% 29.17% 6.65%
ICON Public 8.30%11.70%6.25%

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 95.6% of ICON Public shares are owned by institutional investors. 1.6% of IQVIA shares are owned by insiders. Comparatively, 44.0% of ICON Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IQVIA received 37 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 67.99% of users gave IQVIA an outperform vote while only 65.14% of users gave ICON Public an outperform vote.

CompanyUnderperformOutperform
IQVIAOutperform Votes
635
67.99%
Underperform Votes
299
32.01%
ICON PublicOutperform Votes
598
65.14%
Underperform Votes
320
34.86%

In the previous week, IQVIA had 10 more articles in the media than ICON Public. MarketBeat recorded 10 mentions for IQVIA and 0 mentions for ICON Public. IQVIA's average media sentiment score of 0.94 beat ICON Public's score of 0.75 indicating that IQVIA is being referred to more favorably in the media.

Company Overall Sentiment
IQVIA Positive
ICON Public Positive

IQVIA currently has a consensus price target of $258.40, indicating a potential upside of 19.49%. ICON Public has a consensus price target of $345.30, indicating a potential upside of 8.32%. Given IQVIA's higher possible upside, analysts clearly believe IQVIA is more favorable than ICON Public.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQVIA
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81
ICON Public
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

IQVIA beats ICON Public on 12 of the 18 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IQV vs. The Competition

MetricIQVIACommercial physical research IndustryMedical SectorNYSE Exchange
Market Cap$39.40B$5.03B$4.93B$17.78B
Dividend YieldN/A1.31%5.25%3.62%
P/E Ratio29.5417.27160.9424.29
Price / Sales2.63111.972,242.6714.57
Price / Cash13.6125.6932.5819.17
Price / Book6.463.864.754.56
Net Income$1.36B$133.30M$105.56M$971.75M
7 Day Performance1.37%30.20%116.62%1.88%
1 Month Performance-5.81%17.72%115.19%-0.50%
1 Year Performance1.02%-13.71%122.65%11.76%

IQVIA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICLR
ICON Public
3.0762 of 5 stars
$318.78
+0.9%
$345.30
+8.3%
+40.8%$26.30B$8.12B38.7841,100
INCY
Incyte
4.5895 of 5 stars
$63.22
+1.4%
$73.69
+16.6%
+1.2%$14.20B$3.70B19.162,524Positive News
High Trading Volume
MEDP
Medpace
4.7386 of 5 stars
$404.03
+0.8%
$443.14
+9.7%
+80.9%$12.41B$1.96B41.195,900Positive News
CRL
Charles River Laboratories International
4.173 of 5 stars
$211.60
+0.9%
$256.38
+21.2%
+1.8%$10.90B$4.13B24.8921,800Positive News
NRC
National Research
1.1469 of 5 stars
$25.37
+1.3%
N/A-43.1%$605.84M$148.58M20.46435News Coverage
High Trading Volume
OABI
OmniAb
1.517 of 5 stars
$3.99
-1.7%
$9.00
+125.6%
-17.0%$469.26M$34.16M-6.23106High Trading Volume
MXCT
MaxCyte
2.0181 of 5 stars
$4.24
+1.9%
$8.67
+104.4%
-9.4%$442.66M$41.29M-12.11143Positive News
ABSI
Absci
2.5674 of 5 stars
$3.02
+3.4%
$9.25
+206.3%
+70.6%$341.50M$5.72M-2.60155Gap Up
High Trading Volume
LUNA
Luna Innovations
1.0444 of 5 stars
$3.44
-0.3%
$10.00
+190.7%
-61.5%$116.82M$116.61M-43.00337Upcoming Earnings
NOTV
Inotiv
0.7411 of 5 stars
$1.80
+4.7%
$6.19
+243.8%
-64.6%$46.75M$572.42M-0.652,055Gap Up

Related Companies and Tools

This page (NYSE:IQV) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners